Status message

Active context: kki_bg_colors_yellow

A Phase 3, multicenter, three-week, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of flexible doses of oral Ziprasidone in children and adolescents with Bipolar I disorder (current or most recent episode manic)

Principal Investigator:

This will be a Phase 3, multicenter, 3-week, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and tolerability of flexibly dosed ziprasidone compared with placebo for the treatment of Bipolar I Disorder. 

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.